Arovella Therapeutics (ALA) News
Latest articles and price-sensitive announcements with AI sentiment classification.
ASXNotification regarding unquoted securities - ALA
other announcement
KalkineArovella Therapeutics Updates Investors on iNKT Cell Therapy Platform and ALA-101 Clinical Trial Progress
Arovella Therapeutics (ASX:ALA), a clinical-stage biotech firm developing an "off-the-shelf" invariant Natural Killer T (iNKT) cell therapy platform, held an investor webinar on 12 August 2026 to share updates following the Board of Directors' recent strategic review. Key Highlights Chairman Dr David Williams and Acting CEO Dr Nicole van der Weerden led the webinar on 12 August 2026 at 2:00 PM AEST. Discussion focused on advancing the iNKT cell therapy platform and the imminent clinical devel...
Google NewsArovella Therapeutics Limited (ASX:ALA) Share Market Overview and Healthcare Sector Profile - Kalkine
Arovella Therapeutics Limited (ASX:ALA) Share Market Overview and Healthcare Sector Profile Kalkine
_07_03_2026_03_50_21_133108.jpg&w=3840&q=65)
Arovella Therapeutics Announces Investor Webinar on iNKT Cell Therapy Progress and ALA-101 Clinical Trial
Arovella Therapeutics (ASX:ALA), a clinical-stage biotech firm developing an "off-the-shelf" invariant Natural Killer T (iNKT) cell therapy platform, will host an investor webinar on 12 August 2026 at 2:00 PM AEST to share updates following the Board of Directors' recent strategic review. Key Highlights Investor webinar set for 12 August 2026 at 2:00 PM AEST, hosted by Bell Potter Presentations by Chairman Dr David Williams and Acting CEO Dr Nicole van der Weerden Discussion on company’s iN...
Arovella Therapeutics Ltd (ASX: ALA) Share Price Update: Stock Rises as Health Care Index Closes Lower - Kalkine
Arovella Therapeutics Ltd (ASX: ALA) Share Price Update: Stock Rises as Health Care Index Closes Lower Kalkine
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Why Are Investors Watching (ASX:ALA) in the ASX Smallcap Rally?
Highlights Market focus shifts toward clinical and commercial evidence Funding cycles and execution timelines under closer review Smallcap sentiment shaped by broader ASX rotation signals ASX smallcap health-tech attention is being driven by shifting sentiment, funding conditions, and commercial validation signals across the broader equity market landscape. The discussion around health-tech small-cap proof has re-emerged as market participants reassess h...
Turtle to Clinical Advisory Board&Fiorenza Lead Investigator
other announcement
Arovella Leadership Shift Draws Attention on Clinical Focus
Highlights Leadership transition announced at Arovella Therapeutics Clinical development strategy remains in focus Board signals continuity during transition phase Arovella Therapeutics has announced a leadership transition as the company continues advancing its clinical ambitions and broader biotechnology strategy within the Australian healthcare sector. Australian biotechnology company Arovella Therapeutics (ASX:ALA) has entered a new phase following the appointment of an acting chief...
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
Notification regarding unquoted securities - ALA
other announcement
Notice received under section 249D of the Corporations Act
other announcement
Quarterly Activities/Appendix 4C Cash Flow Report
other announcement
ALA files IND with the U.S. FDA for phase 1 clinical trial
other announcement